Clinical Trials Logo

Fibrosarcoma clinical trials

View clinical trials related to Fibrosarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06387485 Recruiting - Osteosarcoma Clinical Trials

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across 3 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, utilizing 3D printed models and imaging, or the active comparator arm, using only imaging. Primary endpoint: Operative time of surgical procedure. Secondary endpoints: Reduction of blood loss, proportion of postoperative adverse events, and negative tumor margins. Exploratory endpoints: Surgical planning ease, changes in surgical plan, and surgeon satisfaction.

NCT ID: NCT03967834 Recruiting - Soft Tissue Sarcoma Clinical Trials

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

MIRAS
Start date: April 26, 2021
Phase: N/A
Study type: Interventional

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

NCT ID: NCT03899792 Recruiting - Soft Tissue Sarcoma Clinical Trials

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

LIBRETTO-121
Start date: June 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

NCT ID: NCT01567046 Recruiting - Chordoma Clinical Trials

Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

Start date: March 2012
Phase: N/A
Study type: Observational

This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

NCT ID: NCT00356031 Recruiting - Soft Tissue Sarcoma Clinical Trials

Bevacizumab and Radiation Therapy for Sarcomas

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation.